The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for a Marketing Authorization Application for darolutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer who are at high risk for developing metastatic disease.
Praveen Ramakrishnan, MD, spotlights some of the exciting data recently presented across the spectrum of non-Hodgkin lymphoma treatment.
The European Medicines Agency’s Committee for Medicinal Products for Human Use has granted a positive opinion to the fixed-dose combination of venetoclax and obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia.
Douglas W. Blayney, MD, discusses phase II results of the combination of pegfilgrastim and plinabulin, as well as the importance of controlling chemotherapy-induced neutropenia for patients.
The European Medicines Agency has validated a Marketing Authorization Application for tucatinib in combination with trastuzumab and capecitabine for the treatment of adult patients with unresectable locally advanced or metastatic HER2-positive breast cancer, including those with brain metastases, who have received ≥2 prior anti-HER2 treatment regimens.
The FDA has granted a breakthrough therapy designation to the combination of APR-246 and azacitidine for the treatment of patients with myelodysplastic syndromes with a susceptible TP53 mutation.
The combination of ruxolitinib (Jakafi) plus low-dose pegylated interferon-a2 demonstrated an improvement in peripheral blood cell counts bone marrow cellularity and fibrosis, and symptom burden with acceptable toxicity in patients with polycythemia vera or proliferative myelofibrosis.
R. Lor Randall, MD, discusses the referral challenges for orthopedic oncologists and the importance of improving quality of life for patients with metastatic bone disease.
Jacqueline S. Garcia, MD, discusses the design and findings of a phase II trial of navitoclax and details next steps for the BCL-XL/BCL-2 inhibitor.
Ruben Mesa, MD, discusses findings from a pooled analysis of fedratinib at full dose in patients with myelofibrosis who had low platelet counts.
Darolutamide plus androgen deprivation therapy (ADT) led to a significant improvement in overall survival (OS) compared with placebo and ADT in patients with nonmetastatic castration-resistant prostate cancer, according to results from a preplanned final OS analysis of the phase III ARAMIS trial.
Srikanth Nagalla, MD, discusses the management of cancer-related thrombosis in myeloproliferative neoplasms, as well as updates in immune thrombocytopenic purpura.
Thomas J. Scharschmidt, MD, MBOE, discusses the use of targeted muscle reinnervation for amputee patients with cancer as well as therapeutic advances in sarcoma and tenosynovial giant cell tumor.
The FDA has scheduled an Oncologic Drugs Advisory Committee hearing for February 26, 2020, to discuss data supporting a supplemental biologics license application for intravenous ramucirumab injection for use in combination with erlotinib in the frontline treatment of patients with metastatic non–small cell lung cancer whose tumors harbor EGFR Ex19del or Ex21 substitution mutations.
A new drug application has been filed with the Japanese Ministry of Health, Labor and Welfare for manufacturing and marketing approval of cabozantinib for the treatment of patients with unresectable hepatocellular carcinoma following progression on prior systemic therapy.
The European Medicines Agency has validated and is now evaluating a Marketing Authorization Application for the CAR T-cell therapy KTE-X19 for the treatment of adult patients with relapsed/refractory mantle cell lymphoma.
The European Commission has approved apalutamide for use in combination with androgen deprivation therapy for the treatment of adult men with metastatic hormone-sensitive prostate cancer.
C. Parker Gibbs, MD, discusses the research behind p16 and p21 as predictive biomarkers for treatment response in patients with osteosarcoma.
The FDA has granted a priority review designation to a new drug application for selpercatinib (LOXO-292) for the treatment of patients with advanced RET fusion–positive non–small cell lung cancer, RET-mutant medullary thyroid cancer, and RET fusion–positive thyroid cancer.
Larry Anderson, MD, PhD, discusses emerging therapies for patients with multiple myeloma that were highlighted at the 2019 ASH Annual Meeting.
After more than 30 years of leadership as chair of City of Hope’s Department of Hematology & Hematopoietic Cell Transplantation, Stephen J. Forman, MD, has decided to transition out of this role.
A. Oliver Sartor, MD, discusses the development of radiopharmaceuticals in prostate cancer.
Lawrence D. Kaplan, MD, discusses standard frontline treatment in follicular lymphoma, toxicities of some of the newer agents, and preliminary data with bispecific antibodies.
Ankit Kansagra, MD, discusses the evolving use of CAR T-cell therapy in multiple myeloma and lymphoma.
The Centers for Medicare & Medicaid Services has expanded coverage of laboratory diagnostic tests that utilize next-generation sequencing that have been approved or cleared by the FDA for use in patients with germline ovarian or breast cancers.
